[2]Giuliani, S. et al. In a cohort of breast cancer screened patients the proportion of HER2 positive cases is lower than that earlier reported and pathological characteristics differ between HER2 3+ and HER2 2+/Her2 ampli...
BRCA1/2 mutations occurred in 6.6% of patients with human epidermal growth factor receptor 2 (HER2/neu)‐positive breast cancer. However, BRCA mutation status did not affect survival outcomes in patients who had HER2/neu‐positive breast cancer....
This reduction in survival in HER2-positive cases persisted when patients were split into subgroups by ER status, tumour size and age (Table 2). Figure 1 Kaplan–Meier curves for HER2 status. Survival curves showing cumulative survival differences (end point=breast cancer-specific survival) between...
[19] Krop IE, Kim SB, Martin AG, et al. Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): Final overall survival results from a randomised open-l...
Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365(14):1273-1283. Buzdar AU, Ibrahim NK, Francis D, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epi...
Human epidermal growth factor receptor 2 (HER2) positive breast cancer accounts for 20–25% of all breast cancers. Multiple HER2-targeted therapies have been developed over the last few years, including the tyrosine kinase inhibitors (TKI) lapatinib, neratinib, tucatinib, and pyrotinib. These drug...
[1] Shi Q, Xuhong J, Luo T, et al. PIK3CA mutations are associated with pathologic complete response rate to neoadjuvant pyrotinib and trastuzumab plus chemotherapy for HER2-positive breast cancer. Br J Cancer. 2023;128(1):121-129. ...
Patients with HER2-positive metastatic breast cancer experienced a significant survival benefit when treated with fam-trastuzumab deruxtecan compared with trastuzumab emtansine.
respond poorly. This study aimed to identify predictors of response in the neoadjuvant treatment and to assess the discordance rate of HER2 status between pre- and post-treatment specimens in HER2-positive breast cancer.Meth...
Fig. 2 Circ-0003910 was up-regulated in HER2 positive breast cancer cells A-C: Heat map of differentially expressed circRNA; D-F: Scatter plots of differentially expressed circRNA; G:...